Stay updated with breaking news from 80067710. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO – Get Free Report) have received a consensus recommendation of “Hold” from the seven ratings firms that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to […]
Sangamo Therapeutics, Inc. (NASDAQ:SGMO – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the seven ratings firms that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The average 1 year […]
StockNews.com upgraded shares of Sangamo Therapeutics (NASDAQ:SGMO – Free Report) to a sell rating in a report published on Wednesday morning. A number of other brokerages have also recently commented on SGMO. HC Wainwright reiterated a buy rating and set a $5.00 target price on shares of Sangamo Therapeutics in a report on Monday, August […]
Sangamo Therapeutics (NASDAQ:SGMO – Free Report) had its price target trimmed by Truist Financial from $8.00 to $7.00 in a research note released on Tuesday, Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock. Several other equities analysts have also recently issued reports on the stock. Barclays lowered their target price […]
Sangamo Therapeutics, Inc. (NASDAQ:SGMO – Free Report) – Equities research analysts at HC Wainwright cut their Q3 2023 earnings per share (EPS) estimates for Sangamo Therapeutics in a note issued to investors on Monday, August 14th. HC Wainwright analyst P. Trucchio now anticipates that the biopharmaceutical company will earn ($0.38) per share for the quarter, […]